PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
1.18
Positive OCF/share while AGEN is negative. John Neff might see an operational advantage over the competitor.
1.17
Positive FCF/share while AGEN is negative. John Neff might note a key competitive advantage in free cash generation.
0.97%
Positive ratio while AGEN is negative. John Neff might see a superior capital structure versus the competitor.
-3.59
Negative ratio while AGEN is 0.88. Joel Greenblatt would check if we have far worse cash coverage of earnings.
62040.00%
Positive ratio while AGEN is negative. John Neff might see a real competitive edge in cash conversion.